A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease

Journals Menu

Follow SCIRP

ISSN Print: 1949-4998
ISSN Online: 1949-5005
www.scirp.org/journal/health
E-mail: health@scirp.org

"A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease"
written by Shota Saito, Utako Shimizu, Zhang Nan, Junji Yokoyama, Mayumi Watanabe, Kenshi Terajima, Kohei Akazawa,
published by Health, Vol.6 No.1, 2014

has been cited by the following article(s):

[1]	Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence …
	2020

[2]	Biosimilars for the management of inflammatory bowel diseases: economic considerations
	2018

[3]	Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses
	Expert review of pharmacoeconomics & outcomes research, 2014

[1]	Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand Journal of Medical Economics, 2020 DOI:10.1080/13696998.2020.1803889

[2]	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations Current Medicinal Chemistry, 2019 DOI:10.2174/0929867324666170406112304

[3]	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling Health Technology Assessment, 2016 DOI:10.3310/hta20830

Follow SCIRP